跳至主要内容
临床试验/NCT00225719
NCT00225719已完成2 期

Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.

CSL Limited2 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2005年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
CSL Limited
入组人数
180
试验地点
2
主要终点
Efficacy

研究概览

简要总结

Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female 30 - 75 years of age
  • Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the last 14 days

排除标准

  • >50% stenosis by visual angiographic estimation in the left main artery
  • Renal insufficiency
  • Severe liver disease
  • Congestive heart failure as defined by the NYHA classification as functional Class III or Class IV
  • Previous or planned coronary artery bypass surgery

结局指标

主要结局

Efficacy

次要结局

  • Safety

研究者

发起方
CSL Limited
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验